A co-clinical platform to accelerate cancer treatment optimization
A Lunardi, PP Pandolfi - Trends in molecular medicine, 2015 - cell.com
Sophistication in DNA and RNA sequencing technology is unraveling the tremendous
genetic and molecular complexity of human cancer. However, the rate at which this …
genetic and molecular complexity of human cancer. However, the rate at which this …
Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling
G Valiuliene, I Stirblyte, D Cicenaite… - Journal of Cellular …, 2015 - Wiley Online Library
Epigenetic changes play a significant role in leukaemia pathogenesis, therefore histone
deacetylases (HDAC is) are widely accepted as an attractive strategy for acute …
deacetylases (HDAC is) are widely accepted as an attractive strategy for acute …
The case for extracellular Nm23-H1 as a driver of acute myeloid leukaemia (AML) progression
AJ Lilly, FL Khanim, CM Bunce - Naunyn-Schmiedeberg's archives of …, 2015 - Springer
Studies in the 1990s identified a link between extracellular Nm23 proteins and acute
myeloid leukaemia (AML). Confidence in the importance of these observations was …
myeloid leukaemia (AML). Confidence in the importance of these observations was …
Role in chemotherapy
KK Mann, M Lemaire - Arsenic: Exposure Sources, Health …, 2015 - Wiley Online Library
The use of arsenic has been restricted to acute promyelocytic leukemia (APL), although a
significant number of investigations have the potential to broaden the clinical setting for …
significant number of investigations have the potential to broaden the clinical setting for …
Acute Promyelocytic Leukaemia: From a Specific Translocation to Cure by Targeted Therapies
KL Rice, H de Thé - Chromosomal Translocations and Genome …, 2015 - Springer
Acute promyelocytic leukaemia (APL) biology started by the discovery of the driving t (15;
17) translocation in 1977, followed by the unexpected ex vivo differentiation by a hormone …
17) translocation in 1977, followed by the unexpected ex vivo differentiation by a hormone …
[PDF][PDF] p53 as an Effector or Inhibitor of Therapy
J Ablain, B Poirot, C Esnault, J Lehmann-Che - 2015 - researchgate.net
Although integrity of the p53 signaling pathway in a given tumor was expected to be a critical
determinant of response to therapies, most clinical studies failed to link p53 status and …
determinant of response to therapies, most clinical studies failed to link p53 status and …
PML/RARA as the Master Driver of APL Pathogenesis and Therapy Response
Acute promyelocytic leukemia (APL) is a model disease for targeted therapy. APL is caused
by a variety of fusion proteins, all implicating the retinoic acid receptor alpha (RARA). The …
by a variety of fusion proteins, all implicating the retinoic acid receptor alpha (RARA). The …